Wednesday, September 2, 2026

A Busted Businesses or a Cyclical Bottom?

Two U.S. protein-snacking companies lost $6 billion in market value as impairments, inventory growth and margin pressure test whether the category has reached a cyclical bottom.

SMPL $852MBRBR $920M

The Value Road Sep 2 12 clicks

Sep 2 SGMO $60M

Sangamo Bankruptcy (SGMOQ)

Triple S Special Situations Investing 6 clicks

Sep 2 ATMTF $195M

An ATM that starts to spit out cash

The Oak Bloke 7 clicks

From X

@majgeoinvesting Aug 20

Maj Soueidan on X

Can finally believe that $BOSC will make an acquisition? https://t.co/iMwgVmJvux

@BlueDuckCap Aug 20 2 clicks

BDC on X

$XGN bio pharma revenue increased 40% yy in Q2 hitting a quarterly record. What we also love is that the stock trades for 2.5x sales vs a comp set at 10.3x. This is in advance of launching testing for Myositis which is another connective-tissue disorder that requires early diagnosis to treat and prevent serious organ damage. Rheumatologists have requested a calibrated Myositis test w/ 15x more frequency than any other test because the condition is so critical to rule out. Only $XGN will offer this and its coming in the 1H of 2027, maybe Q1 and the additional cost of launch are already baked into the cake.

@stockgutter Aug 20 1 click

SG on X

Worst analyst piece I have seen in years: Litchfield Hills Research puts a 12-month price target of $66 on $FFAI You will be shocked to learn that the small type says: "Litchfield Hills Research LLC has received compensation from the company for distribution and investor targeting services."

@stockgutter Aug 20 1 click

SG on X

$KSCP quarterly results improve but still stink. Now trades for about 1x annualized sales. Note that any valuation metric needs to be taken with a grain of salt here given the heavy dilution. https://t.co/oGq9fRNtNe

@cfrischer1 Aug 19

Charles Frischer on X

$KWY I have attached my notes on Kingsway. I think the company is at an inflection point based upon the excellent quarter they just announced. Very excited to see how the next few years play out for shareholders. I am optimistic. $10 per share should be an excellent entry point. https://t.co/j0rgEf3hUR

@stockgutter Aug 19 1 click

SG on X

@DeepSailCapital @paulcerro There is also a 2x ETF $MRNX that has a reasonable rate but I don't currently see a borrow.

@TimyanBankAlert Aug 19 4 clicks

Timyan Bank Alert on X

QNB Corp. $QNBC Announces Pricing of Common Stock Offering https://t.co/5mPLeT0iSH

@Mike10947310 Aug 19 3 clicks

Mike on X

@mathlonning $SIF especially, I thought the Q was good

Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case

Tectonic Therapeutic's TX45 CpcPH-HFpEF program gains support from Merck's CADENCE data; Phase 1b hemodynamics and cash through Q1 2029 set…

TECX $466M

Equity Eagle Sep 2 2 clicks

EVC Update

EVC reported a solid second quarter and outlook.

EVC $666M

Nat Stewart - Stock Picking Newsletter Sep 1 15 clicks

$LMB: Limbach missed the data center boom. Is that the opportunity? | 1 Main Capital

Limbach's EBITDA fell 30% as organic revenue declined, but 1 Main Capital calls the weakness temporary and views CYMCOR as its first…

LMB $610M

Yet Another Value Podcast Sep 1 9 clicks

GoPro sold itself at 9:20 AM to get ahead of a meme stock

GoPro rushed out its Starman Optical merger after Markiplier-driven buying sent GPRO up roughly 90% premarket, offering shareholders $1.14…

GPRO $275M

Yet Another Value Blog Sep 1 4 clicks

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

Shattuck Labs pivots to DR3-targeted IBD therapy SL-325, funded through a Phase 2b readout as it competes with anti-TL1A drugs.

STTK $638M

Equity Eagle Sep 1

Emerge Commerce ($ECOM.V) FINS Review

Emerge Commerce's $44 million COVID-era acquisitions produced losses and impairments, while modestly improved Q2 liquidity leaves its…

EMCMF $11M

Wolf's Substack Aug 30 6 clicks

NTG Clarity Networks ($NCI.V) FINS Review

NTG Clarity’s $18.6M of Q2 service revenue sat in contract assets, while $4.6M cash burn cut cash to $2.85M and raises liquidity concerns.

NYWKF $12M

Wolf's Substack Aug 28 8 clicks

INMB 2026-08-28

INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment

INmune Bio's Ebstrocel targets recessive dystrophic epidermolysis bullosa with UK, EU and US filings planned by early 2027, while XPro adds…

INMB $56M

Tejo Strategy Investing Aug 28

Late August 2026 Random Ramblings

Higher rates could compress equity multiples and raise AI data center lease costs, while UWMC and Cogent raise questions about CEO-driven…

CCOI $377M

Yet Another Value Podcast Aug 27 13 clicks

The Verra Sneerer (NASDAQ:VRRM)

Verra Mobility renewed Hertz tolling management for five years. AutoKinex lets rental customers buy tolling, fuel and protection products…

VRRM $458M

The Oak Bloke Aug 27 6 clicks

LWAY · long

Lifeway Foods INC

Lifeway Foods holds 95% market share in kefir, is growing 20% to 35%, and trades at 12 times projected 2027 earnings as its capex cycle…

LWAY $328M

Value Investors Club Jun 3

Domo (Arigato), for this potential multi-bagger options trade

Domo’s $400 million sale to Progress would leave a cash-rich public shell with $900 million of NOLs; January 2028 $5 calls cost 22 cents.

DOMO $167M

Triple S Special Situations Investing Aug 27 3 clicks

FUFU 2026-08-27

BitFuFu: A $93 Million Liability No One Can Explain

BitFuFu’s $93.4 million unexplained long-term payable equals 57% of liabilities, overshadowing sharply higher self-mining and hosting…

FUFU $242M

Dorine Cherop Aug 27

Atlas Engineered Products ($AEP.V) FINS Review

Atlas Engineered Products reported Q2 revenue up 19% to $16.2 million, but ended cashless on its credit line as inventory rose 47% and…

APEUF $30M

Wolf's Substack Aug 25 10 clicks

ARQQ 2026-08-25

Arqit Quantum: The Little Boat That Couldn't

Arqit Quantum trades at 397.6x FY26 EV/Sales while facing 5.44 million shares of dilution, cash burn and uncertain recurring revenue.

ARQQ $420M

Luis Cortes Dequidt Aug 25 1 click

The Junk (Mail) Merger Arb

Star Equity’s $5 per-share Harte-Hanks acquisition offers $2.50 cash plus 0.25 STRRP per share after proration, against a $2 break price.

STRR $38MHHS $34M

Triple S Special Situations Investing Aug 24 8 clicks

RCEL 2026-08-24

AVITA Medical: Favorable Reimbursements For Skin Wound Care

AVITA Medical’s more predictable reimbursement, RECELL GO rollout and PermeaDerm economics support adoption, with cash flow breakeven…

RCEL $366M

Myriam Alvarez Aug 24 4 clicks

Aloe Aloe Aloe what 'ave VERRA then?

Verra Mobility's new seven-year Avis agreement replaces a customer worth over 10% of revenue on materially worse economics, exposing…

VRRM $458M

The Oak Bloke Aug 20 13 clicks

Jumia

Jumia’s January 2028 $7/$15 call spread risks $1.15 for up to $6.85 if cost cuts and marketplace growth deliver adjusted EBITDA and…

JMIA $917M

Triple S Special Situations Investing Aug 18 13 clicks

Why DoorDash’s Autonomous Strategy Beats Uber’s Hodgepodge

DoorDash’s integrated autonomous-delivery strategy contrasts with Uber’s 2026 divestment of Serve Robotics, its former delivery-robot…

SERV $386M

MBI Deep Dives Aug 17 4 clicks

Wednesday, September 2, 2026

Maj Soueidan on X

BDC on X

SG on X

SG on X

Charles Frischer on X

SG on X

Timyan Bank Alert on X

Mike on X

Investor Letters

Publications we follow

Newsletters 91

YouTube 4

Blogs 12

Seeking Alpha 36 of 186

X accounts we follow

Investor letters we follow

Sectors